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MicroAbstract 
As oral chemotherapy might reduce physiological and psychological burdens on patients, we 40 
conducted a feasibility study using S-1, an oral fluoropyrimidine, as postoperative 
chemotherapy in 50 patients with curatively resected stage IB-IIIA non-small cell lung cancer. 
The completion rate was 72.0% and the 3-year relapse-free survival rate was 69.4%. This 
protocol seems feasible and may be sufficient to prevent recurrence. 
45 
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Abstract 
Background: Oral adjuvant chemotherapy without hospitalisation might reduce the 
physiological and psychological burden on patients if effectiveness could be guaranteed. We 
conducted a multi-center feasibility study using S-1, an oral derivative of 5-fluorouracil, as 
postoperative adjuvant chemotherapy in patients with curatively resected pathologically stage 50 
IB-IIIA non-small cell lung cancer. Patients and Methods: Adjuvant chemotherapy 
comprised eight courses (4-week administration, 2-week withdrawal) of S-1 at 80-120 
mg/body/day. Fifty-one patients from seven institutions were enrolled in this pilot study, 
from June 2005 to March 2007. The primary endpoint was the completion rate of scheduled 
adjuvant chemotherapy. Secondary endpoints were the incidence and grade of adverse 55 
reactions. Results: Fifty patients were eligible. The completion rate for the planned eight 
courses of S-1 administration was 72.0% (36 patients). Total percentage administration 
amount was 71.1%. Grade 3 adverse reactions such as neutropenia (4.0%), anorexia (4.0%), 
thrombopenia (2.0%), anemia (2.0%), elevated total bilirubin (2.0%), hypokalemia (2.0%), 
nausea (2.0%) and diarrhoea (2.0%) were observed, but no grade 4 adverse effects were 60 
encountered. Overall and relapse-free survival rates at 3 years were 87.7% and 69.4%, 
respectively. Conclusion: Postoperative 1-year administration of S-1 seems feasible as oral 
adjuvant chemotherapy for lung cancer. The oral formulation and low incidence of adverse 
reactions permit treatment on an outpatient basis. The present study would be reasonable to 
follow up with a properly powered phase III trial. 65 
 
Keywords: Non-small cell lung cancer, Adjuvant chemotherapy, Fluoropyrimidine, S-1, 
Feasibility study 
Tsuchiya et al., Page 6 
Introduction 
The results of surgical treatment for lung cancer have been improved by early detection 70 
and meticulous surgical procedures. However, we still face recurrence in patients with 
advanced lung cancer, even after extended surgical treatment. Since 2004, clinical research 
studies have established the efficacy of adjuvant chemotherapy in post-operative patients 
with stage IB-IIIA non-small cell lung cancer (NSCLC).1-3 Standard regimens for adjuvant 
chemotherapy currently use intravenous administration of a platinum doublet. However, oral 75 
adjuvant chemotherapy with uracil-tegafur, which improved survival among patients with 
completely resected stage IB adenocarcinoma, allows completion of the regimen with only 
mild adverse reactions.1 Such oral drugs enable patients to undergo treatment on an outpatient 
basis, and are suitable for maintaining patient quality of life. 
S-1 is a novel oral fluoropyrimidine derivative consisting of tegafur (FT) and two 80 
modulators, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a 
molar ratio of 1:0.4:1.4 FT is a prodrug of 5-fluorouracil (5-FU) and CDHP is a reversible 
competitive inhibitor of dihydropyrimidine dehydrogenase (DPD; EC1.3.1.2), an enzyme 
involved in the degradation of 5-FU. Degradation of FT-derived 5-FU is thus efficiently 
inhibited by CDHP, and 5-FU remains in plasma and tumor tissue longer and at higher levels 85 
than when low-dose 5-FU is continuously infused intravenously. The major toxicities 
associated with fluoropyrimidines are diarrhoea and mucositis.5 Oxo is a reversible 
competitive inhibitor of orotate phosphoribosyltransferase (EC2.4.2.10), a phosphoenzyme 
for 5-FU, and is distributed at high levels in the gastrointestinal (GI) tract after oral 
administration, reducing GI toxicity caused by 5-FU.6 90 
Response rates for platinum doublet therapy in patients with advanced lung cancer are 
30-33%.7 Conversely, S-1 showed a 22% response rate for advanced NSCLC in a previous 
phase II trial,8 raising the question of whether S-1 has sufficient power as adjuvant 
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chemotherapy. In that regard, the therapeutic strategy with oral fluoropyrimidine differs from 
that with intensive platinum doublets. Despite showing a response rate of only 7% for 95 
advanced NSCLC, uracil-tegafur, another oral fluoropyrimidine, could be administered 
long-term (2 years) and, thus, could allow administration of sufficient amounts to prevent 
recurrence or metastasis, because the drug has extremely low toxicity and is easily continued 
as an oral medication.9 Although the exact mechanisms of action accounting for the efficacy 
of uracil-tegafur treatment in the postoperative adjuvant setting remain unclear, long-term 100 
uracil-tegafur administration may inhibit the development of postoperative recurrence 
through antiangiogenic effects in addition to direct cytotoxic effects.10 In terms of S-1-based 
adjuvant chemotherapy, in the field of gastric cancer, a feasibility study has already been 
performed and achieved a high completion rate of 60% and a favorable drug compliance rate 
of 70%.11 Furthermore, a phase III randomized study comparing surgery alone to surgery plus 105 
adjuvant chemotherapy using S-1 was ongoing in 2005.12 Given this background, we 
presumed that if long-term administration could be achieved in the postoperative adjuvant 
setting, similar factors would be applicable even for stage II to IIIA disease because of the 
higher response rate compared to uracil-tegafur. 
Based on similar notions, a feasibility study for adjuvant chemotherapy was reported by 110 
Yano et al. in 2010.13 In that study, 56.7% of patients finished the regimen. Postoperative 
administration of S-1 for 6 months was thus considered feasible as adjuvant chemotherapy 
for NSCLC. However, the administration period of 6 months is half the reported duration of 
the adjuvant chemotherapy with S-112 and the completion rate is unsatisfactorily low despite 
the mildness of adverse reactions. Moreover, survival data from the study have yet to be 115 
reported. 
Tsuchiya et al., Page 8 
To confirm the feasibility of 1-year administration of S-1 and analyse the effect of the 
intervention on prognoses, a multi-center phase II clinical trial was conducted in seven 
facilities. 
 120 
Patients and Methods 
Patient Eligibility 
Patient eligibility required compliance with the following criteria: NSCLC with 
histological proof; pathological stage IB, II, or IIIA NSCLC (according to the fifth edition of 
UICC/AJCC 1997)14 after complete resection; no prior treatment except for surgery; age >20 125 
and <80 years, with sufficient oral intake; and performance status (PS) 0 or 1. Patients also 
had to have adequate organ function (3500 ≤ leukocytes ≤ 12,000/mm3; thrombocytes, 
≥100,000/mm3; total bilirubin, ≤1.5 mg/dl; aspartate aminotransferase and alanine 
aminotransferase, less than twice the normal limits at each institution; blood urea nitrogen, 
≤25 mg/dl; creatinine, less than the normal limits at each institution; and creatinine clearance 130 
(Ccr) as estimated by the Cockcroft-Gault formula, ≥50 ml/min). Patients with a history of 
drug hypersensitivity, serious surgical or non-surgical complications, or active secondary 
cancer were excluded. Pregnant or lactating women were likewise excluded. 
 
Treatment Schedule 135 
Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of 
S-1 (FT, gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 
mg/body/day according to body surface area (BSA): BSA <1.25 m2, 80 mg/day; BSA ≥1.25 
m2 but <1.5 m2, 100 mg/day; and BSA ≥1.5 m2, 120 mg/day. S-1 was administered orally, 
twice daily after meals, starting within 4 weeks after surgery. Every 6 weeks, patients visited 140 
the hospital and drug compliance was checked from the treatment diary. Subjective 
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symptoms, clinical experiment including hematological toxicities and tumor markers were 
also confirmed. The administration dose for the next course was determined after checking 
these data. Doses were modified in accordance with the following guidelines. When adverse 
reactions appeared, the dose was reduced from 120 to 100 mg/day or from 100 to 80 mg/day, 145 
or administration was temporarily discontinued. Restarting was approved when adequate 
organ function was recovered and fulfilled the following criteria: leukocytes, ≥3,000/mm 3; 
neutrophils, ≥1,500/mm3; thrombocytes, ≥100,000/mm3; total bilirubin, ≤1.5 mg/dl; aspartate 
aminotransferase and alanine aminotransferase, less than twice the upper limits of normal at 
each institution; blood urea nitrogen, ≤25 mg/dl; creatinine, less than the upper limit of 150 
normal at each institution; and creatinine clearance (Ccr) as estimated by the Cockcroft-Gault 
formula, ≥50 ml/min. When treatment was restarted within 14 days, the restart was judged to 
represent the same course after temporary discontinuation of drug administration. When 
treatment could not be restarted within 14 days, the course was skipped and restarted as the 
next course. Treatment was discontinued when the patient showed disease recurrence or 155 
adverse reactions that were uncontrollable by dose modification and temporary 
discontinuation of drug administration. If a rest period >4 weeks was required, the patient 
was withdrawn from the study. National Cancer Institute Common Toxicity Criteria 
(NCI-CTC, 1998) were adopted for the evaluation of chemotherapy toxicity. 
 160 
Study Design and Statistical Analysis 
This trial was non-blinded and open-label. The primary endpoint was the completion rate 
of the scheduled adjuvant chemotherapy. Secondary endpoints were the incidence and grade 
of adverse reactions. The number of patients to be enrolled in this study was calculated as 55. 
Assuming a completion rate of 70%, with a planned eligible sample size of 50 patients, the 165 
95% confidence interval (CI) for the completion rate was estimated to range from 55% to 
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82%. This completion rate of 70% means that 70% of patients would complete 48 weeks of 
planned chemotherapy. 
The Kaplan-Meier method was used to estimate the time-to-event functions of 
relapse-free survival and overall survival. Relapse-free survival has been defined as the time 170 
from the date of the start of treatment to the date of disease progression or death (whichever 
occurs first) or the date of last contact. Overall survival has been defined as the time from the 
date of the start of treatment to the date of death or last contact. The log-rank test was used to 
test for possible differences between estimated time-to-event curves. 
 175 
Ethics 
This study was approved by the institutional review board at each site. Patients selected 
whether they would participate in the trial or not after detailed explanation and written 
informed consent was obtained from all patients prior to enrolment. In terms of one 
institution (Nagasaki University Hospital), 52 patients were referred to the trial. Among the 180 
referred patients, 15 patients participated in the trial, 14 patients preferred to received 
uracil-tegafur (p-stage IB), and 23 patients preferred to received standard chemotherapy. 
 
Results 
Patient Characteristics 185 
A total of 51 patients were initially enrolled in the present study. One patients were 
ineligible, who rescinded consent to enter the trial before administration of S-1. Table 1 
shows the characteristics of the 50 eligible patients. The median age of patients was 71.0 
years (range, 32-80 years). Lobectomy was performed in all patients. 
 190 
Drug Compliance 
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Table 2 shows drug compliance in each course and reasons for discontinuation of drug 
administration. The planned eight courses of S-1 were administered to 36 patients (72.0%). 
Among these 36 patients, 25 patients received dose reduction (69.4% of 36 patients). Thirteen 
patients discontinued drug administration because of anorexia, diarrhoea, thrombocytopenia, 195 
elevated total bilirubin, fever, or stomatitis (n=5). Non-iatrogenic reasons for discontinuation 
included patient refusal (n=6), transfer to a different hospital (n=1) and administrative errors 
(n=1). The discontinued case occurred within the third course and drug compliance was 
maintained at >85% (85.4-99.4%) in every course. In the total group of 50 patients, the 
percentage of actual days on which S-1 was administered against the total number of planned 200 
administration days (28 days ×8, i.e., 224 days) was 77.3%. Concerning the amount of drug 
administered, the compliance rate was 71.1%. 
 
Adverse Reactions and Dose Reduction 
Table 3 shows a summary of the adverse reactions encountered. Among the laboratory 205 
findings-based adverse reactions, increased serum total bilirubin was the most frequent, 
occurring in 8 of the 50 patients (16.0%), followed by thorombocytopenia (12.0%), anemia 
(12.0%), and leukocytopenia (10.0%). Among the clinical findings-based adverse reactions, 
anorexia was the most frequent (42.0%), followed by nausea (12.0%), diarrhoea (6.0%), 
pigmentation changes (6.0%), stomatitis (4.0%), malaise (4.0%), and constipation (4.0%). 210 
Concerning the incidence and grade of laboratory findings-based adverse reactions, grade 3 
adverse reactions were seen with neutropenia, thorombocytopenia, anemia, increased serum 
total bilirubin, and hypokalemia. No grade 4 adverse reactions were identified. In clinical 
findings-based adverse reactions, grade 3 adverse reactions were observed with anorexia, 
nausea, and diarrhoea. Again, no grade 4 adverse reactions were encountered. 215 
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The completion rate was 86.7% among cases without adverse reactions (Table 4). When 
adverse reactions occurred, completion rate decreased to 65.7%. However, dose reduction 
clearly increased the completion rate (79.2%). When administration was restarted without a 
dose reduction, the completion rate was significantly lower (36.4%). 
 220 
Survival 
Among the 50 patients followed for survival information, only 13 had died and 37 were 
still alive at the time of analysis. Median follow-up time was 49.0 months (range, 7.3-66.4 
months). At the time of analysis, overall survival rate at 36 months was 87.7% (95%CI, 
75.2-94.4) (Figure 1). Of the 13 patients who died, 8 had experienced a documented relapse 225 
before death. Four patients died of brain infarction, pneumonia, newly developed malignant 
lymphoma, or interstitial pneumonia 9 months after the discontinuation of S-1 administration. 
A total of 14 patients relapsed, and the relapse-free survival rate at 36 months was 69.4% 
(95%CI, 55.2-80.6) (Figure 1). Among the patients who experienced relapse, 6 patients 
experienced intrathoracic relapse, including five with regional lymphatic metastasis and one 230 
with dissemination, and 8 patients showed distant relapse alone.  
 
Discussion 
The present study was undertaken to confirm the feasibility of 1-year oral adjuvant 
chemotherapy with S-1 after standard resection for NSCLC. The completion rate for the 235 
planned eight courses of S-1 administration was 72.0%, which compares favourably to the 
chemotherapy compliance seen on trials of cisplatin-based adjuvant therapies that have 
ranged from 45% to 76% of the intended dose.11-13 Toxicity in the present study was 
significantly less compared with the other regimen. No grade 4 adverse reactions were 
observed throughout the eight courses. Only six grade 3 hematological and four grade 3 240 
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non-hematological adverse events were encountered (20.0% of total). The most common 
adverse reaction was grade 1 anorexia, in 42.0% of patients, and administration for 
outpatients was easily continued. Compared to postoperative adjuvant chemotherapy study 
using uracil-tegafur, another oral fluoropyrimidine, the frequency of grade 3 adverse 
reactions was less than 4%. The most common adverse reaction was grade 1 gastrointestinal 245 
toxicity, including anorexia, nausea and vomiting in around 10% of patients, representing an 
extremely low frequency.1 Conversely, studies of platinum-based postoperative adjuvant 
chemotherapy have indicated that the frequency of grade 3 or more adverse reactions was 
more than 69% even with carboplatin-based therapies.16,18 Accordingly, S-1 is considered to 
cause intermediate adverse reactions, allowing acceptable compliance. Furthermore, the 250 
possibility of outpatient treatment with S-1 is convenient for both doctors and patients. 
In the present study, the total percentage administration days and percentage 
administration dose were 77.3% and 71.1%. Whether a dose reduction of 70% allows 
sufficient power to prevent recurrence of lung cancer remains unclear. In analysis of a phase 
III study of postoperative gastric cancer,12 when protocol completion cases were divided into 255 
two groups according to compliance with S-1 administration, the 5-year survival curves for 
patients with ≥90% compliance and patients with 70% to <90% compliance overlapped 
(in-house experimental data; Taiho Pharmaceutical). We therefore believe a dose reduction of 
70% provides sufficient adjuvant chemotherapy for lung cancer with S-1, as in gastric cancer. 
Further studies and long-term observations are necessary to clarify the remaining issues. 260 
The regimen in the present study was based on the seminal phase III randomized study in 
postoperative gastric cancer.12 Among the 517 patients in the safety population who received 
S-1, treatment was continued for 12 months in 340 patients (65.8%). In the present study, 
completion rates were 8% or more higher than those from the study in gastric cancer. In 
addition, our results showed incidences of hematological and non-hematological adverse 265 
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reactions were both lower than in the gastric cancer study. As patients in the gastric cancer 
study displayed rather advanced disease and received D2 or more aggressive gastrectomy 
with frequent combined organ resections, patients who undergo standard resection for lung 
cancer might show better general and intestinal conditions for oral chemotherapy. 
In a recent feasibility study of adjuvant chemotherapy with S-1 for NSCLC,13 the 270 
administration period of 6 months and the cycle of 2-week administration and 1-week 
withdrawal differed from the protocol applied in our study. That study demonstrated no 
hematological or non-hematological grade 4 adverse reactions throughout the eight courses, 
very similar to our study. Conversely, completion rate of the planned eight courses of S-1 
administration was 56.7%. The reason for the relatively low completion rate was attributed to 275 
the high age of patients and the high incidence of patients declining to continue treatment.13 
In the present study, dose reductions were performed without hesitation. When adverse 
reactions were encountered, dose reduction obviously improved the completion rate to 79.2%, 
compared to 36.4% without dose reduction. As a result, we achieved a high completion rate 
of 72.0%. The duration of S-1 administration is another area of discrepancy. Administration 280 
of 5-FU is known to be more effective in producing direct cytotoxic effects against human 
tumor cells using lower doses for longer time periods than using higher doses for shorter 
times.19 Our opinion is that at least a year of S-1 is warranted, unless clinical evidence to the 
contrary is identified. 
The overall survival rate among patients with stage IB resected NSCLC was similar to 285 
that among patients with stage IIA or more resected NSCLC (data not shown). These data 
indicate that oral S-1 treatment might have sufficient power to improve survival even in 
postoperative patients with severe stage NSCLC. Further follow-up survival data are needed 
for the present study. In addition, randomized phase II and III clinical trials of adjuvant 
chemotherapy containing S-1 for NSCLCs (WJOG4107 and JCOG0707) are ongoing. The 290 
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JCOG0707 phase III study is comparing survival data and compliance between uracil-tegafur 
and S-1 for stage IA (>2 cm) and IB postoperative patients. The results will provide more 
reliable data on whether S-1 alone is worthwhile as an option for adjuvant chemotherapy. 
One limitation of the present study was the difficulty in confirming true drug compliance. 
We checked drug compliance from the treatment diary every 6 weeks when the patient visited 295 
the hospital, but had no way of ensuring that the patient had made true declarations regarding 
drug intake. Although most seminal studies have not mentioned this point and one study 
applied a similar method,1 investigators must keep in mind that all such oral administration 
studies conducted on an outpatient basis carry this problem in confirming true drug 
compliance. 300 
Although S-1 is not well known in Western countries, various clinical trials of S-1-based 
chemotherapy have been performed or are ongoing for advanced NSCLC, particularly in 
Japan.20 Among chemotherapy-naïve patients with advanced NSCLC, a phase III trial by the 
West Japan Oncology Group showed oral S-1 plus carboplatin was non-inferior in terms of 
overall survival when compared to paclitaxel plus carboplatin.21 Comparisons of 305 
5-FU-related enzymes of NSCLC in such patients have indicated that low expression of 
thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are associated with 
better survival in S-1 plus CBDCA therapy, but not in PTX and CBDCA therapy.22 As S-1 is 
a prodrug of 5-FU, we believe the expression of TS, a 5-FU-targeting enzyme, and DPD, a 
5-FU-degrading enzyme, are important in determining susceptibility to S-1. Further study of 310 
rational differences in 5-FU-related enzymes might be necessary, as expressions of TS and 
DPD might differ in NSCLC between Western and Eastern populations. 
 
Conclusion 
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Postoperative 1-year oral administration of S-1 seems feasible as an adjuvant 315 
chemotherapy for lung cancer. A high completion rate was achieved when administration 
doses were decreased by one rank when adverse events were encountered. The oral 
formulation and low incidence of adverse reactions permit treatment on an outpatient basis. 
The present findings suggest that follow-up with a properly powered phase III study 
comparing treatment using S-1 to the standard of care for adjuvant chemotherapy would be 320 
reasonable. 
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Clinical Practice Points 
The current standard regimen for adjuvant chemotherapy of NSCLC is intravenous 325 
administration of a platinum doublet. However, a seminal study indicated adjuvant 
chemotherapy with uracil-tegafur, an oral fluoropyrimidine, could improve survival among 
patients with completely resected stage IB adenocarcinoma. The biggest advantage of such 
therapy is the low toxicity and easy continuation as oral medication, which can allow 
long-term administration in amounts sufficient to prevent recurrence. The anti-tumor 330 
mechanisms of oral fluoropyrimidine are presumed to differ from those of platinum doublets; 
long-term administration can inhibit the development of postoperative recurrence through 
antiangiogenic effects as well as by direct cytotoxic effects. 
S-1 is a novel oral fluoropyrimidine derivative consisting of the 5-fluorouracil prodrug 
tegafur (FT) and two modulators. A modulator of 5-chloro-2,4-dihydroxypyridine (CDHP) is 335 
a reversible competitive inhibitor of dihydropyrimidine dehydrogenase (DPD), an enzyme 
involved in the degradation of 5-FU. As S-1 shows 180-times stronger DPD-inhibiting effect 
and a higher response rate from patients than uracil-tegafur (22% vs. 7% for advanced 
NSCLC), we considered this therapy would likely prove beneficial for patients with 
surgically resected pathological IB to IIIA NSCLC. 340 
The new findings of the present study were that we could achieve a favorable completion 
rate for 1-year S-1-based adjuvant chemotherapy and also showed the possibility of good 
prognosis for stage IB to IIIA NSCLC in an adjuvant setting. The clinical impact in the 
foreseeable future is that the present study confirmed S-1-based adjuvant chemotherapy as 
worthy of follow-up in a properly powered phase III study comparing with the standard of 345 
care for adjuvant chemotherapy. 
Tsuchiya et al., Page 18 
Acknowledgements  
We wish to thank Dr. Sumihisa Honda for providing statistical advice. We are also 
grateful to Taiho Pharmaceutical for technical support and invaluable assistance. 350 
 
Disclosures 
All authors report that they have no relevant relationships to disclose. 
 
355 
Tsuchiya et al., Page 19 
References 
1. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with 
uracil-tegafur for adenocarcinoma of the lung: Japan Lung Cancer Research Group on 
Postsurgical Adjuvant Chemotherapy. N Engl J Med 2004; 350:1713–21  
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in 360 
patients with completely resected non-small-cell lung cancer: International Adjuvant Lung 
Cancer Trial Collaborative Group. N Engl J Med 2004; 350:351–60 
3. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in 
resected non-small-cell lung cancer: National Cancer Institute of Canada Clinical Trials 
Group; National Cancer Institute of the United States Intergroup JBR.10 Trial 365 
Investigators. N Engl J Med 2005; 352:2589–97 
4. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 
5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective 
cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 1996; 
7:548–57 370 
5. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol 1984; 
2:1289–304  
6. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal 
toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 
53:4004–9 375 
7. Kubota K. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung 
cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 22:254 
8. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in 
advanced non-small-cell lung cancer: S-1 Cooperative Study Group (Lung Cancer 
Working Group). Br J Cancer 2001; 85(7):939–43 380 
Tsuchiya et al., Page 20 
9. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in 
UFT phase II study. Cancer Chemother Pharmacol 1988; 22:333–8. 
10. Basaki Y, Chikahisa L, Aoyagi K, et al. Gamma-hydroxybutyric acid and 5-fluorouracil, 
metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. 
Angiogenesis 2001; 4:163-73 385 
11. Kinoshita T, Nashimoto A, Yamamura Y. Feasibility study of adjuvant chemotherapy 
with S-1 (TS-1;tegafur,gimeracil,oteracil potassium) for gastric cancer. Gastric Cancer 
2004; 7:104-9 
12. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant Chemotherapy for Gastric 
Cancer with S-1, an Oral Fluoropyrimidine: ACTS-GC Group. N Engl J Med 2007; 390 
357(18):1810-20  
13. Yano T, Yamazaki K, Maruyama R, et al. Feasibility study of postoperative adjuvant 
chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung 
cancer—LOGIK 0601 study: Lung Oncology Group in Kyushu (LOGIK). Lung Cancer 
2010; 67:184–7  395 
14. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 
1997; 111:1707–10 
15. Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung 
cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res 2005; 
11:5017s-21s  400 
16. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus 
observation in patients with completely resected stage IB–IIIA non-small cell lung cancer 
(Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled 
trial. Lancet Oncol 2006; 7: 719–27 
Tsuchiya et al., Page 21 
17. Butts CA, Ding K, Seymour L, et al. Randomized Phase III Trial of Vinorelbine Plus 405 
Cisplatin Compared With Observation in Completely Resected Stage IB and II 
Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol 2009; 
28:29-34 
18. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant Paclitaxel Plus Carboplatin 
Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 410 
With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North 
Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-51  
19. Paula M, Calabro-Jones, Byfield JE, et al. Time-dose relationships for 5-Fluorouracil 
cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982; 42:4413-20.  
20. Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. 415 
Gen Thorac Cardiovasc Surg 2010; 58:3-13 
21. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus 
carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced 
non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 
2010; 28:5240-6 420 
22. Takeda M, Okamoto I, Hirabayashi N, et al. Thymidylate synthase and 
dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 
plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011; 73:103-9 
Tsuchiya et al., Page 22 
Figure Legends 425 

















Evaluable cases (n=50) 
          Overall survival 
           Median: 43.2 months 
           3 yr overall survival: 87.7% 
          Relapse-free survival  
           Median : 49.5 months 





Table 1  Patient Characteristics (n = 50)     
Variables  n Percentage 
Sex Male 34  68.0  
 Female 16  32.0  
Age (years) <50 4  8.0  
 50-59  8  16.0  
 60-69 11  22.0  
 ≥70 27  54.0  
 Mean, 66.6; median 71.0    
Type of resection  Lobectomy 50  100.0  
Lymph node 
dissection 
ND1 2  4.0  
 ND2 48  96.0  
Histology Adenocarcinoma 29  58.0  
 SCC 19  38.0  
 Others 2  4.0  
Pathological TNM 
stage 
IB 28  56.0  
 IIA 10  20.0  
 IIB 5  10.0  
 IIIA 7  14.0  
      
SCC, squamous cell carcinoma 
 
Table 2  Drug Compliance (each course) (n = 50)  
Course 
No. of patients 
entering course 
% Reason for discontinuation 
1 50 100  
   
Grade 2 stomatitis (patient refusal) 
Recurrence 
2 48 96.0   
   Grade 3 thrombocytopenia 
   
Grade2 thrombocytopenia and  
Grade 1 fever 
   Grade 2 anorexia (patient refusal) 
   Grade 2 anorexia (patient refusal) 
   Grade 3 anorexia 
   Grade 3 diarrhoea 
   Grade 3 elevated total bilirubin 
   Grade 2 anorexia (patient refusal) 
3 40 80.0  
   
Grade 1 anorexia and Grade 1 elevated 
total bilirubin (patient refusal) 
   Patient refusal 
   Change of hospital 
4 37 74.0  
7   Stopped administration by mistake 
8 36 72.0  
Complete    
    
 
Table 3  Adverse Reactions (n = 50)      
 
 Grade Total 
 1 2 3 4 (incidence; percentage) 
Laboratory findings      
 Neutropenia 0 0 2 0 4.0 
 Leukocytopenia 1 4 0 0 10.0 
 Thrombocytopenia 1 4 1 0 12.0 
 Anemia 1 4 1 0 12.0 
 Increase in serum AST or ALT 1 0 0 0 2.0  
 Increase in serum total bilirubin 5 2 1 0 16.0 
 Hypokalaemia 0 0 1 0 2.0  
 Elevation of amylase 1 0 0 0 2.0  
Clinical findings      
 Fever 2 0 0 0 4.0 
 Anorexia 16 3 2 0 42.0 
 Nausea 3 2 1 0 12.0 
 Diarrhoea 2 0 1 0 6.0 
 Stomatitis 1 1 0 0 4.0 
 Malaise 1 1 0 0 4.0 
 Pigmentation 1 2 0 0 6.0 
 Constipation 1 1 0 0 4.0 
 Neural disturbance 1 0 0 0 2.0  
 Dehydration 0 1 0 0 2.0  
 Lacrimation 1 0 0 0 2.0  
Grade 2 or more thrombocytopenia and other adverse reactions of Grade 3 or more match the 
criteria for dose reduction 
 
Table 4  Effect of Dose Reduction on Adverse Reactions (n = 50) 
  n Completed cases Completion rate (%) 
Without adverse reaction 15 13 86.7 
With adverse reactions 35 23 65.7 
 with dose reduction 24 19 79.2 
 without dose reduction 11 4 36.4 
     
 
